Panax ginseng as an adjuvant treatment for Alzheimer's disease |
Kim, Hyeon-Joong
(Ginsentology Research Laboratory and Department of Physiology, College of Veterinary Medicine, Konkuk University)
Jung, Seok-Won (Ginsentology Research Laboratory and Department of Physiology, College of Veterinary Medicine, Konkuk University) Kim, Seog-Young (Department of Convergence Medicine, University of Ulsan College of Medicine and Institute of Life Science, Asan Medical Center) Cho, Ik-Hyun (Department of Convergence Medical Science, College of Korean Medicine, Kyung Hee University) Kim, Hyoung-Chun (Neuropsychopharmacology and toxicology program, College of Pharmacy, Kangwon National University) Rhim, Hyewhon (Center for Neuroscience, Korea Institute of Science and Technology) Kim, Manho (Department of Neurology, Neuroscience Research Center, Seoul National University Hospital) Nah, Seung-Yeol (Ginsentology Research Laboratory and Department of Physiology, College of Veterinary Medicine, Konkuk University) |
1 | Cho IH. Effects of panax ginseng in neurodegenerative diseases. J Ginseng Res 2012;36:342-53. https://doi.org/10.5142/jgr.2012.36.4.342. DOI |
2 | Kim HJ, Kim P, Shin CY. A comprehensive review of the therapeutic and pharmacological effects of ginseng and ginsenosides in central nervous system. J Ginseng Res 2012;37:8-29. https://doi.org/10.5142/jgr.2013.37.8. |
3 | Sheng C, Peng W, Xia ZA, Wang Y, Chen Z, Su N, Wang Z. The impact of ginsenosides on cognitive deficits in experimental animal studies of Alzheimer's disease: a systematic review. BMC Complement Altern Med 2015;15:386. https://doi.org/10.1186/s12906-015-0894-y. DOI |
4 | Pyo MK, Choi SH, Hwang SH, Shin TJ, Lee BH, Lee SM, Lim YH, Kim DH, Nah SY. Novel glycolipoproteins from ginseng. J Ginseng Res 2008;35:92-103. |
5 | Hwang SH, Shin TJ, Choi SH, Cho HJ, Lee BH, Pyo MK, Lee JH, Kang J, Kim HJ, Park CW, et al. Gintonin, newly identified compounds from ginseng, is novel lysophosphatidic acids-protein complexes and activates G protein-coupled lysophosphatidic acid receptors with high affinity. Mol Cells 2012;33:151-62. https://doi.org/10.1007/s10059-012-2216-z. DOI |
6 |
Wang YH, Du GH. Ginsenoside Rg1 inhibits |
7 | Qiu J, Li W, Feng SH, Wang M, He ZY. Ginsenoside Rh2 promotes nonamyloidgenic cleavage of amyloid precursor protein via a cholesteroldependent pathway. Genet Mol Res 2014;13:3586-98. https://doi.org/10.4238/2014.May.9.2. DOI |
8 | Zhao H, Di J, Liu W, Liu H, Lai H, Lu Y. Involvement of GSK3 and PP2A in ginsenoside Rb1's attenuation of aluminum-induced tau hyperphosphorylation. Behav Brain Res 2013;241:228-34. https://doi.org/10.1016/j.bbr.2012.11.037. DOI |
9 | Li L, Liu J, Yan X, Qin K, Shi M, Lin T, Zhu Y, Kang T, Zhao G. Protective effects of ginsenoside Rd against okadaic acid-induced neurotoxicity in vivo and in vitro. J Ethnopharmacol 2011;138:135-41. https://doi.org/10.1016/j.jep.2011.08.068. DOI |
10 | Li H, Kang T, Qi B, Kong L, Jiao Y, Cao Y, Zhang J, Yang J. Neuroprotective effects of ginseng protein on PI3K/Akt signaling pathway in the hippocampus of Dgalactose/AlCl3 inducing rats model of Alzheimer's disease. J Ethnopharmacol 2016;179:162-9. https://doi.org/10.1016/j.jep.2015.12.020. DOI |
11 | Hwang SH, Shin EJ, Shin TJ, Lee BH, Choi SH, Kang J, Kim HJ, Kwon SH, Jang CG, Lee JH, et al. Gintonin, a ginseng-derived lysophosphatidic acid receptor ligand, attenuates Alzheimer's disease-related neuropathies: involvement of non-amyloidogenic processing. J Alzheimer's Dis 2012;31:207-23. DOI |
12 | Moon J, Choi SH, Shim JY, Park HJ, Oh MJ, Kim M, Nah SY. Gintonin administration is safe and potentially beneficial in cognitively impaired elderly. Alzheimer Dis Assoc Disord 2017;Oct 12. https://doi.org/10.1097/WAD.0000000000000213 [ahead of print]. |
13 | Lee BH, Choi SH, Kim HJ, Jung SW, Kim HK, Nah SY. Plant lysophosphatidic acids: a rich source for bioactive lysophosphatidic acids and their pharmacological applications. Biol Pharm Bull 2016;3:156-62. https://doi.org/10.1248/bpb.b15-00575. |
14 | Choi SH, Hong MK, Kim HJ, Ryoo N, Rhim H, Nah SY, Kang LW. Structure of ginseng major latex-like protein 151 and its proposed lysophosphatidic acidbinding mechanism. Acta Crystallogr D Biol Crystallogr 2015;71:1039-50. https://doi.org/10.1107/S139900471500259X. DOI |
15 | Salous AK, Panchatcharam M, Sunkara M, Mueller P, Dong A, Wang Y, Graf GA, Smyth SS, Morris AJ. Mechanism of rapid elimination of lysophosphatidic acid and related lipids from the circulation of mice. J Lipid Res 2013;54:2775-84. https://doi.org/10.1194/jlr.M039685. DOI |
16 | Kim MS, Yu JM, Kim HJ, Kim HB, Kim ST, Jang SK, Choi YW, Lee DI, Joo SS. Ginsenoside Re and Rd enhance the expression of cholinergic markers and neuronal differentiation in Neuro-2a cells. Biol Pharm Bull 2014;37:826-33. DOI |
17 | Kim HJ, Kim DJ, Shin EJ, Lee BH, Choi SH, Hwang SH, Rhim H, Cho IH, Kim HC, Nah SY. Effects of gintonin-enriched fraction on hippocampal cell proliferation in wild-type mice and an APPswe/PSEN-1 double Tg mouse model of Alzheimer's disease. Neurochem Int 2016;101:56-65. https://doi.org/10.1016/j.neuint.2016.10.006. DOI |
18 | Kim HJ, Park SD, Lee RM, Lee BH, Choi SH, Hwang SH, Rhim H, Kim HC, Nah SY. Gintonin attenuates depressive-like behaviors associated with alcohol withdrawal in mice. J Affect Disord 2017;215:23-9. DOI |
19 | Kim S, Kim MS, Park K, Kim HJ, Jung SW, Nah SY, Han JS, Chung C. Hippocampus-dependent cognitive enhancement induced by systemic gintonin administration. J Ginseng Res 2016;40:55-61. https://doi.org/10.1016/j.jgr.2015.05.001. DOI |
20 | Schmitt FA, Cragar D, Ashford JW, Reisberg B, Ferris S, Mobius HJ, Stoffler A. Measuring cognition in advanced Alzheimer's disease for clinical trials. J Neural Transm Suppl 2002;62:135-48. |
21 | Bodick NC, Offen WW, Shannon HE, Satterwhite J, Lucas R, van Lier R, Paul SM. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord 1997;11(Suppl. 4):S16-22. DOI |
22 | Schmitt B, Bernhardt T, Moeller HJ, Heuser I, Frolich L. Combination therapy in Alzheimer's disease: a review of current evidence. CNS Drugs 2004;18(13):827-44. DOI |
23 |
Lu X, Wang HT, Li CL, Gao XH, Ding JL, Zhao HH, Lu YL. Ginsenoside Rb1 protects PC12 cells against |
24 | Patel L, Grossberg GT. Combination therapy for Alzheimer's disease. Drugs Aging 2011;28(7):539-46. https://doi.org/10.2165/11591860-000000000-00000. DOI |
25 | Manoharan S, Guillemin GJ, Abiramasundari RS, Essa MM, Akbar M, Akbar MD. The role of reactive oxygen species in the pathogenesis of Alzheimer's disease, Parkinson's disease, and Huntington's disease: a mini review. Oxid Med Cell Longev 2016;2016, 8590578. https://doi.org/10.1155/2016/8590578. |
26 | Choi SH, Jung SW, Lee BH, Kim HJ, Hwang SH, Kim HK, Nah SY. Ginseng pharmacology: a new paradigm based on gintonin-lysophosphatidic acid receptor interactions. Front Pharmacol 2015;6:245. https://doi.org/10.3389/fphar.2015.00245. |
27 | Seo JS, Yun JH, Baek IS, Leem YH, Kang HW, Cho HK, Lyu YS, Son HJ, Han PL. Oriental medicine Jangwonhwan reduces Abeta(1-42) level and beta-amyloid deposition in the brain of Tg-APPswe/PS1dE9 mouse model of Alzheimer disease. J Ethnopharmacol 2010;128:206-12. https://doi.org/10.1016/j.jep.2010.01.014. DOI |
28 |
Kim J, Kim SH, Lee DS, Lee DJ, Kim SH, Chung S, Yang HO. Effects of fermented ginseng on memory impairment and |
29 |
Shin K, Guo H, Cha Y, Ban YH, Seo DW, Choi Y, Kim TS, Lee SP, Kim JC, Choi EK, et al. |
30 |
Kim HJ, Shin EJ, Lee BH, Choi SH, Jung SW, Cho IH, Hwang SH, Kim JY, Han JS, Chung C, et al. Oral administration of gintonin attenuates cholinergic impairments by scopolamine, amyloid- |
31 | Creeley CE, Wozniak DF, Nardi A, Farber NB, Olney JW. Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain. Neurobiol Aging 2008;29:153-67. https://doi.org/10.1016/j.neurobiolaging.2006.10.020. DOI |
32 | Zadori D, Veres G, Szalardy L, Klivenyi P, Toldi J, Vecsei L. Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets. J Alzheimers Dis 2014;42(Suppl. 3):S177-87. https://doi.org/10.3233/JAD-132621. DOI |
33 | Lazarov O, Hollands C. Hippocampal neurogenesis: learning to remember. Prog Neurobiol 2016;138-140:1-18. https://doi.org/10.1016/j.pneurobio.2015.12.006. DOI |
34 | Uzun S, Kozumplik O, Folnegovic-Smalc V. Alzheimer's dementia: current data review. Coll Antropol 2011;35:1333-7. |
35 | Hugel HM. Brain food for Alzheimer-free ageing: focus on herbal medicines. Adv Exp Med Biol 2015;863:95-116. https://doi.org/10.1007/978-3-319-18365-7-5. |
36 | Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 2007;6:521-32. https://doi.org/10.1038/nrd2094. DOI |
37 | Tian J, Shi J, Zhang X, Wang Y. Herbal therapy: a new pathway for the treatment of Alzheimer's disease. Alzheimers Res Ther 2010;2:30. https://doi.org/10.1186/alzrt54. DOI |
38 | Wang Y, Yang G, Gong J, Lu F, Diao Q, Sun J, Zhang K, Tian J, Liu J. Ginseng for Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials. Curr Top Med Chem 2016;16(5):529-36. DOI |
39 | Choi JG, Kim N, Huh E, Lee H, Oh MH, Park JD, Pyo MK, Oh MS. White ginseng protects mouse hippocampal cells against amyloid-beta oligomer toxicity. Phytother Res 2017;31:497-506. https://doi.org/10.1002/ptr.5776. DOI |
40 | Lee MR, Yun BS, In OH, Sung CK. Comparative study of korean white, red, and black ginseng extract on cholinesterase inhibitory activity and cholinergic function. J Ginseng Res 2011;35:421-8. https://doi.org/10.5142/jgr.2011.35.4.421. DOI |
41 | Heo JH, Lee ST, Chu K, Oh MJ, Park HJ, Shim JY, Kim M. An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer's disease. Eur J Neurol 2008;15:865-8. https://doi.org/10.1111/j.1468-1331.2008.02157.x. DOI |
42 | Heo JH, Lee ST, Oh MJ, Park HJ, Shim JY, Chu K, Kim M. Improvement of cognitive deficit in Alzheimer's disease patients by long term treatment with Korean red ginseng. J Ginseng Res 2011;35:457-61. https://doi.org/10.5142/jgr.2011.35.4.457. DOI |
43 | Lee ST, Chu K, Sim JY, Heo JH, Kim M. Panax ginseng enhances cognitive performance in Alzheimer disease. Alzheimer Dis Assoc Disord 2008;22:222-6. https://doi.org/10.1097/WAD.0b013-31816c92-6. DOI |
44 |
Zuroff L, Daley D, Black KL, Koronyo-Hamaoui M. Clearance of cerebral |
45 |
Wu J, Yang H, Zhao Q, Zhang X, Lou Y. Ginsenoside Rg1 exerts a protective effect against |
46 |
Liu J, Yan X, Qi L, Li L, Hu G, Li P, Zhao G. Ginsenoside Rd attenuates |
47 |
Huang T, Fang F, Chen L, Zhu Y, Zhang J, Chen X, Yan SS. Ginsenoside Rg1 attenuates oligomeric |
48 | Bolos M, Perea JR, Avila J. Alzheimer's disease as an inflammatory disease. Biomol Concepts 2017;8:37-43. https://doi.org/10.1515/bmc-2016-0029. |
49 | Heo JH, Park MH, Lee JH. Effect of Korean red ginseng on cognitive function and quantitative EEG in patients with Alzheimer's disease: a preliminary study. J Altern Complement Med 2016;22:280-5. https://doi.org/10.1089/acm.2015.0265. DOI |
50 |
Habib A, Sawmiller D, Tan J. Restoring soluble amyloid precursor protein |
51 | Wang Y, Liu J, Zhang Z, Bi P, Qi Z, Zhang C. Anti-neuroinflammation effect of ginsenoside Rbl in a rat model of Alzheimer disease. Neurosci Lett 2011;487:70-2. https://doi.org/10.1016/j.neulet.2010.09.076. DOI |
52 | Joo SS, Lee DI. Potential effects of microglial activation induced by ginsenoside Rg3 in rat primary culture: enhancement of type A Macrophage Scavenger Receptor expression. Arch Pharm Res 2005;28:1164-9. DOI |
53 | Nah SY. Ginseng ginsenoside pharmacology in the nervous system: involvement in the regulation of ion channels and receptors. Front Physiol 2014;5:98. https://doi.org/10.3389/fphys.2014.00098. |
54 | Wang ZY, Liu JG, Li H, Yang HM. Pharmacological effects of active components of Chinese herbal medicine in the treatment of Alzheimer's disease: a review. Am J Chin Med 2016;44(8):1525-41. DOI |
55 | Yang WT, Zheng XW, Chen S, Shan CS, Xu QQ, Zhu JZ, Bao XY, Lin Y, Zheng GQ, Wang Y. Chinese herbal medicine for Alzheimer's disease: clinical evidence and possible mechanism of neurogenesis. Biochem Pharmacol 2017;141:143-55. https://doi.org/10.1016/j.bcp.2017.07.002. DOI |
56 | Brekhman II, Dardymov IV. New substances of plant origin which increase nonspecific resistance. Annu Rev Pharmacol 1969;9:419-30. https://doi.org/10.1146/annurev.pa.09.040169.002223. DOI |
57 | Nah SY, Kim DH, Rhim H. Ginsenosides: are any of them candidates for drugs acting on the central nervous system? CNS Drug Rev 2007;13:381-404. https://doi.org/10.1111/j.1527-3458.2007.00023.x. |
58 | Dai D, Zhang CF, Williams S, Yuan CS, Wang CZ. Ginseng on cancer: potential role in modulating inflammation-mediated angiogenesis. Am J Chin Med 2017;45(1):13-22. https://doi.org/10.1142/S0192415X17500021. DOI |
59 | Jiao R, Liu Y, Gao H, Xiao J, So KF. The anti-oxidant and antitumor properties of plant polysaccharides. Am J Chin Med 2016;44(3):463-88. https://doi.org/10.1142/S0192415X16500269. DOI |
60 | Choi RJ, Roy A, Jung HJ, Ali MY, Min BS, Park CH, Yokozawa T, Fan TP, Choi JS, Jung HA. BACE1 molecular docking and anti-Alzheimer's disease activities of ginsenosides. J Ethnopharmacol 2016;190:219-30. https://doi.org/10.1016/j.jep.2016.06.013. DOI |
61 | Karpagam V, Sathishkumar N, Sathiyamoorthy S, Rasappan P, Shila S, Kim YJ, Yang DC. Identification of BACE1 inhibitors from Panax ginseng saponins-An Insilco approach. Comput Biol Med 2013;43:1037-44. https://doi.org/10.1016/j.compbiomed.2013.05.009. DOI |
62 | Yan X, Hu G, Yan W, Chen Y, Yang F, Zhang X, Zhao G, Liu J. Ginsenoside Rd promotes non-amyloidogenic pathway of amyloid precursor protein processing by regulating phosphorylation of estrogen receptor alpha. Life Sci 2017;168:16-23. https://doi.org/10.1016/j.lfs.2016.11.002. DOI |
63 |
Cao G, Su P, Zhang S, Guo L, Zhang H, Liang Y, Qin C, Zhang W. Ginsenoside Re reduces |
64 | Fang F, Chen X, Huang T, Lue LF, Luddy JS, Yan SS. Multi-faced neuroprotective effects of Ginsenoside Rg1 in an Alzheimer mouse model. Biochim Biophys Acta 2012;1822:286-92. https://doi.org/10.1016/j.bbadis.2011.10.004. DOI |
65 | Shi C, Zheng D, Fang L, Wu F, Kwong WH, Xu J. Ginsenoside Rg1 promotes nonamyloidgenic cleavage of APP via estrogen receptor signaling to MAPK/ERK and PI3K/Akt. Biochim Biophys Acta 2012;1820:453-60. https://doi.org/10.1016/j.bbagen.2011.12.005. DOI |
66 | Qiao C, Den R, Kudo K, Yamada K, Takemoto K, Wati H, Kanba S. Ginseng enhances contextual fear conditioning and neurogenesis in rats. Neurosci Res 2005;51:31-8. https://doi.org/10.1016/j.neures.2004.09.004. DOI |
67 |
Saba E, Jeon BR, Jeong DH, Lee K, Goo YK, Kwak D, Kim S, Roh SS, Kim SD, Nah SY, et al. A novel Korean red ginseng compound gintonin inhibited inflammation by MAPK and |
68 | Lee BH, Kim HK, Jang M, Kim HJ, Choi SH, Hwang SH, Kim HC, Rhim H, Cho IH, Nah SY. Effects of gintonin-enriched fraction in an atopic dermatitis animal model: involvement of autotaxin regulation. Biol Pharm Bull 2017;40:1063-70. https://doi.org/10.1248/bpb.b17-00124. DOI |
69 | Yu Y, He J, Zhang Y, Luo H, Zhu S, Yang Y, Zhao T, Wu J, Huang Y, Kong J, et al. Increased hippocampal neurogenesis in the progressive stage of Alzheimer's disease phenotype in an APP/PS1 double transgenic mouse model. Hippocampus 2009;19:1247-53. https://doi.org/10.1002/hipo.20587. DOI |
70 | Sun GG, Shih JH, Chiou SH, Hong CJ, Lu SW, Pao LH. Chinese herbal medicines promote hippocampal neuroproliferation, reduce stress hormone levels, inhibit apoptosis, and improve behavior in chronically stressed mice. J Ethnopharmacol 2016;193:159-68. https://doi.org/10.1016/j.jep.2016.07.025. DOI |
71 | Hooper NM. Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein. Biochem Soc Trans 2005;33:335-8. https://doi.org/10.1042/BST0330335. DOI |
72 | Lee CH, Kim JH. A review on the medicinal potentials of ginseng and ginsenosides on cardiovascular diseases. J Ginseng Res 2014;38(3):161-6. https://doi.org/10.1016/j.jgr.2014.03.001. DOI |
73 | Nag SA, Qin JJ, Wang W, Wang MH, Wang H, Zhang R. Ginsenosides as anticancer agents: in vitro and in vivo activities, structure-activity relationships, and molecular mechanisms of action. Front Pharmacol 2012;3:25. https://doi.org/10.3389/fphar.2012.00025. |
74 | Burns A, Iliffe S. Alzheimer's disease. BMJ 2009;338:b158. DOI |
75 | Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362:329-44. https://doi.org/10.1056/NEJMra0909142. DOI |
76 | Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12:383-8. DOI |
77 | Hollands C, Bartolotti N, Lazarov O. Alzheimer's disease and hippocampal adult neurogenesis; exploring shared mechanisms. Front Neurosci 2016;10:178. https://doi.org/10.3389/fnins.2016.00178. |
78 | Mudher A, Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci 2002;25:22-6. DOI |
79 | Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-47. DOI |
80 | Martorana A, Esposito Z, Koch G. Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease? CNS Neurosci Ther 2010;16:235-45. https://doi.org/10.1111/j.1755-5949.2010.00175.x. |
81 | Bagyinszky E, Giau VV, Shim K, Suk K, An SSA, Kim S. Role of inflammatory molecules in the Alzheimer's disease progression and diagnosis. J Neurol Sci 2017;376:242-54. https://doi.org/10.1016/j.jns.2017.03.031. DOI |
82 | Hroudov J, Singh N, Fisar Z. Mitochondrial dysfunctions in neurodegenerative diseases: relevance to Alzheimer's disease. Biomed Res Int 2014;2014:1-9. https://doi.org/10.1155/2014/175062. |
![]() |